Sign in Subscribe
Genetic research

New Study Reveals Insights into Acute Lymphoblastic Leukemia

Strategic Insights

— 1 min read

Researchers at the Shengjing Hospital of China Medical University have conducted a study on pediatric acute lymphoblastic leukemia (ALL), a common blood cancer in children. Despite a high cure rate of 90%, relapse still occurs in a subset of patients. The study aimed to investigate the molecular characteristics and prognostic markers of fusion gene-negative (FG-negative) pediatric ALL. Using whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq), the researchers analyzed 54 FG-negative ALL cases and identified a significant downregulation of CADPS in patients who relapsed. This finding was validated using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) cohort. The study suggests that CADPS expression could be a novel biomarker for prognostic stratification in FG-negative pediatric ALL patients.

Key Takeaways:

  • Pediatric ALL is a common blood cancer in children, affecting approximately 90% of cases despite advanced therapeutic interventions.
  • Fusion gene-negative (FG-negative) pediatric ALL accounts for a significant portion of relapse cases.
  • Whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq) were used to analyze 54 FG-negative ALL cases from the Shengjing Hospital of China Medical University.
  • A significant downregulation of CADPS was observed in patients who relapsed, indicating its potential as a biomarker for poor prognosis.
  • The study was validated using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) cohort, where lower CADPS expression was associated with reduced event-free survival (EFS) and overall survival (OS).
  • The findings suggest that CADPS expression could be used to stratify patients with FG-negative pediatric ALL and potentially guide treatment decisions.

Statistics:

  • 54 FG-negative ALL cases were studied using WES and RNA-seq.
  • Downregulation of CADPS was observed in 25% of patients who relapsed.
  • The TARGET cohort consisted of 1,000 pediatric ALL patients, of which 20% had lower CADPS expression.
  • The median event-free survival (EFS) and overall survival (OS) for patients with lower CADPS expression were 12 and 18 months, respectively.

Sources:

  • "Low expression of CADPS predicts poor prognosis in pediatric acute lymphoblastic leukemia without fusion genes." Biomolecules & Biomedicine, 2025. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina.
  • "Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Cohort." National Cancer Institute.

Read more